Acute Respiratory Infection (ARI) PCR-confirmed Respiratory Syncytial Virus (RSV) PCR-confirmed Influenza PCR-confirmed SARS-CoV-2
Conditions
Interventions
Group 1: Patients aged = 18 years hospitalized due to an acute episode of a respiratory infection and meeting the eligibility criteria.
Sponsors
CAPNETZ STIFTUNG, Geschäftsstelle an der Medizinischen Hochschule Hannover
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Willingness to participate (signed informed consent) - Admitted to hospital as inpatient - Meet the ARI case definition (Presence of at least 2 respiratory symptoms/signs for at least 24 hours before hospital admission OR at least 1 respiratory symptom/sign AND 1 systemic symptom/sign for at least 24 hours before hospital admission) - Onset of ARI signs/symptoms not more than 10 days before enrollment - Enrolled max. 72h after admission to hospital
Exclusion criteria
Exclusion criteria: - No ability to follow study procedures (in the opinion of the investigator) - Participation in an investigational study/clinical trial - Enrolled in the BUCOSS Hosp study within the previous 90 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To describe the prevalence of RT-PCR-confirmed RSV among hospitalized patients aged =50 years with ARI. 2. To describe the prevalence of RT-PCR-confirmed RSV among hospitalized patients aged 18-49 years with ARI. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To describe the prevalence of RT-PCR-confirmed Influenza and of RT-PCR-confirmed SARS-CoV-2 among hospitalized patients aged =18 years with ARI. 2. To estimate the seasonal incidence of ARI hospitalizations in patients aged =18 years with (a) RT-PCR-confirmed RSV, (b) RT-PCR-confirmed influenza, and (c) RT-PCR confirmed SARS-CoV-2. 3. To describe co-infections with other major respiratory pathogens among hospitalized adults aged =18 years with RT-PCR-confirmed RSV-positive ARI. 4. To describe the duration of illness and type of ARI symptoms/signs of hospitalized patients aged =18 years with (a) RT-PCR-confirmed RSV, (b) RT-PCR-confirmed influenza, and (c) RT-PCR confirmed SARS-CoV-2. 5. To describe and compare the demographic and clinical characteristics of hospitalized ARI patients aged =18 years with (a) RT-PCR-confirmed RSV, (b) RT-PCR-confirmed influenza, (c) RT-PCR confirmed SARS-CoV-2, and (d) other RT-PCR confirmed pathogens. 6. To describe and compare clinical course and clinical outcome within the follow-up period of hospitalized patients aged =18 years with ARI with (a) RT-PCR-confirmed RSV, (b) RT-PCR-confirmed Influenza, and (c) RT-PCR-confirmed SARS-CoV-2. 7. To describe and compare complications among hospitalized patients aged =18 years with (a) RT-PCR confirmed RSV, (b) RT-PCR-confirmed Influenza, and (c) RT-PCR-confirmed SARS-CoV-2. 8. To describe health care resource utilization (HCRU) and cost of illness within a follow-up period of 28 and 90 days, in hospitalized patients aged =18 years with ARI with (a) RT-PCR-confirmed RSV, (b) RT-PCR-confirmed Influenza, and (c) RT-PCR-confirmed SARS-CoV-2. 9. To describe the impact on health-related quality of life (HRQoL) within the follow-up period among hospitalized patients aged =18 years with ARI, with (a) RT-PCR-confirmed RSV, (b) RT-PCR-confirmed Influenza, and (c) RT-PCR-confirmed SARS-CoV-2. | — |
Countries
Germany
Contacts
Public ContactGernot Rohde
Universitätsklinikum Frankfurt Zentrum für Innere Medizin, Klinik I: Pneumologie und Allergologie
Outcome results
None listed